Filing Flows › Revolution Medicines (RVMD) › Q3 2026
Revolution Medicines (RVMD) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Revolution Medicines (RVMD) reported revenue of $198M for the third quarter 2026 (Q3 2026). Operating margin was -188.9%, net loss $407M (206.2% of revenue).
Revolution Medicines, Q3 2026: revenue $198M, operating margin -188.9%, net loss $407M, operating cash flow −$416M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $198M | — | — |
| Operating profit | −$373M | — | — |
| Net earnings | −$407M | — | — |
| Operating cash flow | −$416M | — | — |
What changed
Revenue was $197.6M in Q3 2026.
Operating costs exceeded revenue by $373.1M, an operating margin of -188.9%. The quarter ended with a net loss of $407.5M.
Operating cash flow was −$415.6M. Non-cash charges added back $2.6M of depreciation and amortization and $62.6M of share-based compensation. Working capital and other items used $73.5M. Capital expenditures of $3.7M exceeded it, leaving free cash flow of −$419.3M.
Questions
What was Revolution Medicines' revenue in the third quarter 2026?
Revolution Medicines (RVMD) reported revenue of $198M for the third quarter 2026 (Q3 2026).
Was Revolution Medicines profitable in the third quarter 2026?
Operating loss was $373M (-188.9% of revenue) and net loss $407M.